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Abstract
Background: Delays in tuberculosis (TB) diagnosis, particularly in prisons, is associated with detrimental outcomes.
The new GeneXpert MTB/RIF assay (Xpert) offers accurate and rapid diagnosis of active TB, but its performance in
improving case detection in high-transmission congregate settings has yet to be evaluated. We assessed the
diagnostic accuracy of a single Xpert assay in an intensified case finding survey among HIV-infected prisoners in
Malaysia.
Methods: HIV-infected prisoners at a single site provided two early-morning sputum specimens to be examined
using fluorescence smear microscopy, BACTEC MGIT 960 liquid culture and a single Xpert. The sensitivity,
specificity, negative and positive predictive values of Xpert were calculated relative to gold-standard results using
MGIT 960 liquid culture. Relevant clinical and demographic data were used to examine correlates of active TB
disease.
Results: The majority of enrolled subjects with complete data (N=125) were men (90.4%), age <40 years (61.6%)
and had injected drugs (75.2%). Median CD4 lymphocyte count was 337 cells/µL (IQR 149-492); only 19 (15.2%)
were receiving antiretroviral therapy. Of 15 culture-positive TB cases, single Xpert assay accurately detected only
eight previously undiagnosed TB cases, resulting in a sensitivity, specificity, positive predictive value and negative
predictive value of 53.3% (95% CI 30.12-75.2%), 100% (95% CI 96.6-100%), 100% (95% CI 67.56-100%) and 94.0%
(95% CI 88.2-97.1%), respectively. Only 1 of 15 (6.7%) active TB cases was smear-positive. The prevalence (12%)
of undiagnosed active pulmonary TB (15 of 125 prisoners) was high and associated with longer duration of drug use
(AOR 1.14, 95% CI 1.03-1.26, for each year of drug use).
Conclusions: Single Xpert assay improved TB case detection and outperformed AFB smear microscopy, but yielded
low screening sensitivity. Further examination of the impact of HIV infection on the diagnostic performance of the new
assay alongside other screening methods in correctional settings is warranted.
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Introduction
Tuberculosis (TB) remains a major public health problem
particularly in low/middle-income countries (LMIC). More than
80% of the global TB burden and TB-related deaths were
reported from 22 high-burden LMIC in 2011 [1]. With the
current modest annual decline in TB incidence (2%), many
countries will be unable to achieve the Stop TB Partnership
goal of halving TB incidence by 2015 [2]. Ambitious targets
were recently set by the Partnership for the post-2015 era [3].
The spread of multidrug resistant TB (MDR-TB), the
detrimental convergence with HIV infection and the
unavailability of rapid diagnostic tools have contributed to the
failure of global TB control [4–6]. Moreover, through altering the
clinical and bacteriological presentations, HIV infection has
contributed to the delay in diagnosing active TB disease,
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leading to increased morbidity and mortality and enhancement
of transmission within communities [7–9]. These problems are
further magnified in criminal justice settings where TB is a
major contributing factor to the disproportionately high
morbidity and mortality among prisoners [10,11]. Globally, poor
prison living conditions, overcrowding, the concentration of
people at high TB risk and the limited access to health services
inside these congregate settings convert prisons into reservoirs
fuelling the TB and MDR-TB epidemics into surrounding
communities [12]. A systematic review confirmed the
contribution of exposure in prisons to the population’s TB
burden and showed that attributed fractions were 8.5% and
6.3% of overall TB cases in high- and low/middle-income
countries, respectively [13]. Delay in TB diagnosis, due to
limited screening procedures, inaccuracy of diagnostic
algorithms and lack of adequate laboratory facilities, is
recognized as a major limitation for TB control efforts in
correctional settings [8,14–16]. This contributes not only to
increased unfavorable disease outcomes but also to onward
disease transmission to other inmates [9,16–20]. The current
World Health Organization (WHO) symptom-based screening
algorithm for prisons has proven to be diagnostically
inadequate [21], therefore, in order to achieve effective TB
control, the currently-recommended passive case detection
needs to be coupled with an active case finding program,
particularly in congregate settings and especially among HIV-
infected individuals [7,22].
GeneXpert MTB/RIF (Xpert), a new nucleic acid amplification
technology, offers rapid and accurate diagnostic results from
biological specimens with minimal staff training requirements
[20,23,24]. The analysis of this new technology as a point-of-
treatment diagnostic tool in five distinct LMIC sites showed high
sensitivity and specificity for the diagnosis of active TB (97%
and 99.2%, respectively) and the detection of rifampicin (RIF)
resistance (97.6% and 98.1%, respectively), the cornerstone of
TB treatment regimens [20]. A recent review of published
evaluation reports confirmed that the use of Xpert as an initial
test replacing smear microscopy was highly accurate [23]. In
2010 and with the encouraging initial evaluation reports, the
WHO endorsed Xpert to be used as the initial TB diagnostic
test for individuals with HIV-infection or those suspected of
having MDR-TB [25].
Though a dynamic transmission model predicted that the
deployment of Xpert in annual TB screening surveys effectively
reduces overall TB and MDR-TB prevalence in prisons of
Former Soviet Union (FSU) countries, the utilization of this new
technology in intensified case finding and its impact on TB
burden in prisons of LMIC and where high prevalence of HIV
exists has not yet been examined [26,27]. We aimed to
estimate the diagnostic accuracy of a single Xpert assay and to
assess correlates of active TB disease among HIV-infected
inmates of a Malaysian prison.
Methods
Study Design
We conducted a cross-sectional intensified TB case finding
survey among inmates housed in dedicated HIV units in
Malaysia’s largest prison.
Study Setting
Malaysia is a middle-income country with an estimated
intermediate TB incidence and mortality rates in 2011 (81 and
5.7 per 100,000 populations, respectively). Nine percent of the
overall incident TB cases were estimated to be among people
living with HIV/AIDS (PLWHA) [1]. Despite the adoption of
international guidelines, TB incidence in Malaysia has
remained stagnant over the past ten years [1,28]. Malaysia’s
incarceration rate is among the highest in the region (138 per
100,000 population), primarily attributed to the criminalization
of illicit drug possession, one of the main components of the
drug control policy in the country [29,30]. Moreover, people
who inject drugs (PWID) represent the majority (75%) of HIV-
infected individuals. HIV testing of prisoners is mandatory, with
high (6%) HIV prevalence among Malaysian prisoners and 15
times higher than that of the general population [30]. HIV-
infected prisoners are segregated in dedicated housing units.
Prison-based TB control measures are limited and only passive
case detection is deployed in prisons nationwide. The study
was conducted in Kajang prison, Malaysia’s largest prison and
designated as a high-security central prison located in
Selangor State. Maximum prison census capacity is 3500, yet
currently houses more than 4000 inmates at any one time,
operating at 119% of its actual capacity [31].
Study Population
From October to December 2012, all HIV-infected inmates
housed in dedicated units in Kajang’s male and female prisons
were approached for study participation. Group information
sessions were conducted to assess interest and written
informed consent was individually obtained thereafter.
Prisoners with the following criteria were excluded from the
survey: those with a negative confirmatory HIV test, those
receiving anti-TB medications at the time of the survey, or
those with anticipated release within 24 hours. Inmates who
provided written informed consent were asked to produce two
early-morning sputum specimens on two consecutive days in
accordance with WHO recommendations [32]. A structured
survey was used to collect socio-demographic information,
incarceration history (total correctional institution entry times
and years spent in incarcerations), substance abuse practices
(recent heroin use within the 30 days before incarceration, any
injection drug use, duration of drug use in years and current
treatment with methadone within the prison) and TB and HIV
clinical data (previous TB diagnosis, previous TB screening,
current antiretroviral therapy prescription). For reporting TB-
related symptoms, we utilized two WHO-recommended clinical
algorithms: the correctional TB screening scoring and the four-
symptom clinical algorithm for HIV-associated TB disease. In
the former guidance, the WHO recommends screening for
active TB in inmates reporting a score of 5 or more using the
Xpert in Intensified TB Case Finding in Prison
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following scoring system: a) cough for more than 2 weeks and
sputum production (2 points for each); and b) loss of weight in
the past 3 months, recent loss of appetite, and chest pain (1
point for each) [22]. In the latter, the WHO recommends that
the presence of any one of the following symptoms (any
duration of cough, fever, night sweats and weight loss)
necessitates active TB diagnostic work-up [33]. Body mass
index (BMI) was calculated using weight and height and
stratified as underweight if BMI <18.5 kg/m2. Additionally, blood
samples were sent for HIV confirmation using
electrochemiluminescent immunoassay technique, CD4
lymphocyte count, and quantitative HIV-1 RNA assessment.
Sputum Specimen Collection and Processing
Enrolled subjects were asked to provide two sputum
specimens (>2mL each). Sputum samples were not induced,
but collection was directly-observed by one investigator
(HAAA). One direct (unprocessed) sputum specimen from each
participant was analyzed onsite using GeneXpert MTB/RIF v
4.3 (Cepheid, Sunnyvale, CA) according to manufacturer’s
instructions using 1 mL of sputum samples and 1:2 ratio of
processing solution (isopropanol and NaOH) [20]. The
remainder of the first specimen and the second-day sputum
specimen were sent to a quality-assured reference laboratory
for smear fluorescence microscopy examination and
mycobacteriological liquid culture. Upon arrival at the
laboratory, samples were stored at 4 °C for next-day
processing, which included decontamination using N-acetyl-L-
cysteine and sodium hydroxide and centrifugation before
staining a sample from the deposit using Auramine-O phenol
staining for fluorescence microscopy as the primary smear
microscopy examination method. Regardless of smear
microscopy results, pellets were inoculated into the liquid
medium mycobacteria growth indicator tube (MGIT) 960 culture
system (BD Diagnostics, USA). Molecular genetic Genotype
Mycobacterium CM assay (Hain Lifescience, Germany) was
utilized for mycobacterium species identification following
positive mycobacterial growth. The reference laboratory utilizes
BACTEC MGIT 960 liquid culture system to determine drug
susceptibility testing (DST) for isoniazid, rifampicin,
streptomycin and ethambutol with the confirmation of MDR-TB
(resistance to isoniazid and rifampicin) using Genotype
MTBDRplus assay (Hain Lifescience, Germany).
Statistical Analysis
The study reporting conforms to the STARD guidelines for
diagnostic accuracy reporting (www.stard-statement.org/). The
collected data was entered and descriptive and logistic
regression analyses were performed using SPSS v19 (IBM
Corporation, Armonk, NY). Frequencies were calculated for
categorical variables and median with standard deviation (SD)
or interquartile range (IQR) were calculated for continuous
variables depending on whether the data were normally
distributed or not, respectively. Chi square and Student t-test
were utilized to compare results of categorical and continuous
variables between Xpert-negative/culture-positive and Xpert-
positive/culture-positive active TB groups. Sensitivity,
specificity, positive (PPV) and negative (NPV) predictive values
of the Xpert and their respective 95% confidence intervals
(95% CI) were calculated compared to the results of the gold-
standard MGIT 960 liquid culture using OpenEpi v 2.3.1 [34]. .
Bivariate logistic regression model was investigated and
variables with significance level of p<0.2 were entered the
multivariate regression analysis, and controlled for other
potential confounders, to investigate correlates of active TB
disease (defined by positive result on liquid culture) in this
sample. Factors were considered independently associated
with active TB disease at the significance level of p<0.05.
Continuous variables were analyzed as numbers. The cut-off
values used to dichotomize CD4 lymphocyte count (100
cells/µL) and the HIV viral load (100,000 copies/mL) were
made based on the clinical significance [35]. For variables
identified as being strongly collinear with each other (age,
duration of drug use and duration of cigarette smoking), only
one final model was used that was associated with the most
optimal goodness-of-fit using the Akaike Information Criterion
(AIC).
Ethics Statement
The study protocol was reviewed and approved by the
Medical Ethics Committee of the University of Malaya Medical
Centre (UMMC). Following the group information session,
prisoners expressing further interest in participation were met
individually to be provided with explanation about the survey
process and to seek written informed consent. During the
confidential session, a patient information sheet that contains
information about the study components and its significance to
both participants and researchers was provided to each
potential participant and explained thoroughly thereafter.
Individuals who agreed to participate in the study were asked
to sign a standard consent form, which contains details about
the name, identity card number, home address and that s/he
understood the nature of the study and her/his right of
withdrawal at any time during the study. These data were
requested in order to follow up on participants in whom TB
diagnosis is made after their release. Though detailed
information about the importance of early diagnosis of active
TB disease among HIV-infected individuals was highlighted, we
affirmed that the participation was completely voluntary.
Security officers were not alerted about any Individual who
chose not to participate in the survey or withdraw during the
study process in order to ensure that they were not in any way
disadvantaged. To further ensure this, all collected information
including prisoners’ participation status was kept strictly
confidential.
Results
As of October 2012, there were 149 prisoners housed in the
prison’s dedicated HIV units. Of these, 125 participants had
complete data for analysis. Reasons for exclusion were (Figure
1): release within 24 hours (N=4); active TB cases currently
taking anti-TB medications (N=9); considered too dangerous by
prison authorities to transport (N=2); death (N=3); and negative
HIV confirmatory test (N=6). Characteristics of the final sample
(N=125) are summarized in Table S1.
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Figure 1.  The recruitment and findings flowchart.  
doi: 10.1371/journal.pone.0073717.g001
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Despite having a high risk for TB, only one-third (34.4%) of
subjects reported ever being screened for TB before while 36
(28.8%) subjects reported having previously been treated for
active TB, mostly (75%) within the past five years. More than
half (53.6%) of those surveyed were eligible (CD4 count ≤350
cells/µL) for antiretroviral therapy (ART), but only a total of 19
(15.2%) were prescribed ART at the time of the survey. The
median CD4 lymphocyte count was 337 cells/µL (IQR 149-492)
and the median HIV viral load was 28,042 copies/mL (IQR
1,138-73,566.50).
Two-thirds of participants (68%) reported having at least one
of the four symptoms recommended by the WHO for clinical
screening algorithm among HIV-infected individuals and 10
(8%) had ≥5 points using the WHO clinical scoring system
[22,33]. Neither of the two clinical screening algorithms was
associated with active TB disease in this sample (OR 1.34,
p=0.64 and OR 0.80, p=0.84, respectively). Median BMI was
22.3 kg/m2 (SD 3.25) and being underweight (BMI <18.5
Kg/m2) was not associated with having active TB disease (OR
1.96, p=0.43)
The study revealed a very high prevalence of undiagnosed
active pulmonary TB (PTB) disease (12%, 15 out of 125
screened subjects) and overall TB prevalence when current
active TB cases are added (16.7%, 24 out of 143 total HIV-
infected prisoners). With the use of conventional fluorescence
microscopy at the reference laboratory, all but one of the active
TB cases had negative smear examination from the two
sputum specimens. The single Xpert assay examination
detected Mycobacterium tuberculosis accurately in sputa in
eight (53.3%) of the culture-confirmed active TB cases. The
assay however missed the diagnosis of seven active TB cases
confirmed later by the liquid culture giving a sensitivity,
specificity, PPV and NPV of 53.3% (95% CI 30.1-75.2%),
100% (95% CI 96.6-100%), 100% (95% CI 67.6-100%) and
94.0% (95% CI 88.2-97.1%), respectively (Table 1). Xpert was
negative in a single case of Mycobacterium scrofulaceum
detected subsequently by culture. Overall, the active case
finding using Xpert increased TB case detection by one-fold
over the current, passive, case detection (eight and nine active
TB cases, respectively). Xpert-negative/ culture-positive
subjects were more likely to have CD4 lymphocyte count more
than 100 cells/µL (p=0.01) compared to Xpert-positive/culture-
positive cases (Table 2). No rifampicin resistance was reported
by Xpert in this sample, which was confirmed by the reference-
laboratory mycobacteriology DST, giving 100% specificity for
rifampicin resistance detection.
On univariate analysis (see Table S1), a number of
unadjusted covariates significant at p<0.2 including age (OR
1.12, 95% CI 1.02-1.22, p=0.02), living in a crowded house
before incarceration (OR 2.23, 95% CI 0.74-6.67, p=0.15), drug
use duration (OR 1.14, 95% CI 1.03-1.26, p=0.01), recent
alcohol use (OR 2.56, 95% CI 0.68-9.62, p=0.16), years of
smoking cigarettes (OR 1.08, 95% CI 1.00-1.17, p=0.04), CD4
lymphocyte count ≤100 cells/µL (OR 3.17, 95% CI 0.95-10.55,
p=0.06) and HIV-1 RNA of more than 100,000 (OR 3.04, 95%
CI 0.91-10.20, p=0.07). Given that age, duration of drug use
and years of cigarette smoking were identified as being
collinear, separate multivariate logistic regression models using
goodness-of-fit showed that the best model associated with
active pulmonary TB was duration of drug use (adjusted OR
1.14, 95% CI 1.03-1.26, p=0.01 for every year of drug use).
The other covariates no longer remained significant after
controlling for these variables (Table S1).
Discussion
In this intensified TB case-finding survey, we report for the
first time, the diagnostic performance of a single GeneXpert
MTB/RIF assay in improving pulmonary TB case detection
among HIV-infected inmates of a middle-income country
prison. Overall, undiagnosed active TB disease was
remarkably high (12%) among this HIV-infected inmate
population housed in dedicated HIV units. With a very high
sputum AFB smear-negativity, a single Xpert had a limited
sensitivity for the diagnosis of active TB disease (53.3%) but
high specificity for active TB disease (100%) and rifampicin
resistance (100%) detection compared to the liquid culture. The
new convenient assay markedly increased the number of
active TB cases detected in this population, potentially at much
earlier TB disease burden, where profoundly symptomatic
disease is common at the time of clinical presentation.
Importantly in this study, the single Xpert impressively
outperformed the fluorescence smear microscopy examination.
This confirms findings from earlier evaluation studies
conducted in geographically distinct settings and corroborates
the WHO guidance on replacing smear microscopy with Xpert
as the primary diagnostic tool for active TB among HIV infected
individuals [20,25,36]. Similar utilization of a single Xpert assay
in an active case finding among household contacts with
unknown HIV status in Tanzania had 40% higher yield than
smear microscopy examination [37].
We postulated that the low sensitivity reported in this sample
might be related to several factors. Cumulative data from
different settings confirmed the impact of smear-negative
microscopy status on the Xpert accuracy, which can be
improved by increasing the number of analyzed sputa [20,23].
This observation is probably related to the low bacillary load
given that Xpert requires a minimal threshold of 131 bacilli/mL
(compared to 10-100 bacilli/mL for culture) [38]. Lawn SD, et al
reported a similarly low (43.4%) Xpert sensitivity from a TB
screening before ART initiation with prevalent smear negativity
in South Africa, which improved modestly when a second
sample was analyzed (62.3%) [39]. In HIV settings with
Table 1. The diagnostic accuracy of a single GeneXpert
MTB/RIF assay in this sample.
Parameter Xpert (single) 95% Confidence Interval
Sensitivity 53.3% (8 out of 15) 30.12-75.2%
Specificity 100% (110 out of 110) 96.6-100%
PPV 100% (8 out of 8) 67.56-100%
NPV 94.0% (100 out of 117) 88.2-97.1%
Xpert = GeneXpert MTB/RIF; PPV = Positive Predictive Value; NPV = Negative
Predictive Value
doi: 10.1371/journal.pone.0073717.t001
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considerable smear-negative TB disease, a single Xpert
analysis is often deployed due to resource constraints.
HIV infection, on the other hand, complicates the diagnosis
of active TB through reducing the accuracy of available
diagnostic tools [40]. A diagnostic evaluation from a
predominantly HIV-infected community in Tanzania showed
that the vast majority (88.9%) of smear-negative TB cases
were among PLWHA [41]. While HIV infection limits the
sensitivity of smear microscopy in diverse settings, irrespective
of the immunological status [42–44], the impact of HIV infection
Table 2. Comparative analysis between Xpert-negative/
Culture-positive and Xpert-positive/Culture-positive
subjects.
Variables Categories
Xpert-/
Culture+
Xpert+/
Culture+ P value
Age (mean, years)  42.6 40.6 0.58
Gender Male 7 7 0.33
 Female andtransgender 0 1  
Total duration of previous
incarcerations (mean,
months)
 83.82 66.77 0.59
Recent use of heroin No 0 2 0.26
 Yes 7 6  
Injection drug use No 2 1 0.44
 Yes 5 7  
Drug use duration (mean,
years)  23.0 23.9 0.77
Current methadone
therapy No 7 7 0.53
 Yes 0 1  
Recent cigarette smoking No 0 1 0.53
 Yes 7 7  
Current antiretroviral
therapy No 6 7 0.73
 Yes 1 1  
Previous history of TB No 5 7 0.45
 Yes 2 1  
2-morning sputum
specimens No 0 1 0.53
 Yes 7 7  
WHO 4-symptom
algorithm Negative 2 2 0.66
 Positive 5 6  
WHO TB symptom scoring <5 scores 7 7 0.53
 ≥5 scores 0 1  
Body mass index (mean,
Kg/m2)  21.8 20.5 0.31
CD4 lymphocyte count
(cells/µL) ≤100 0 5 0.01
 >100 7 3  
HIV-1 RNA level
(copies/mL) <100,000 6 3 0.13
 ≥100,000 1 4  
doi: 10.1371/journal.pone.0073717.t002
on Xpert diagnostic accuracy is yet to be established. In 5
LMIC sites, the overall sensitivity of Xpert was modestly lower
among HIV-infected than HIV-uninfected (93.9% vs 98.4%;
p=0.02) individuals [20]. A similar reduced trend in the
diagnostic utility of Xpert among 496 archived sputum samples
from TB suspects was found in South Africa among HIV-
infected and HIV-uninfected (69.6% vs 82.9%; p=0.09) patients
with significantly lower NPV (78.3% vs 90.3%; p<0.01) for HIV-
infected and non-infected patients, respectively [36]. On the
other hand, two clinical evaluation studies among symptomatic
TB suspects in Peru [45] and Tanzania [41] reported no
differences in the diagnostic accuracy of Xpert among HIV-
infected and non-infected patients. A recent review of related
evaluation studies revealed heterogeneity in reported
accuracies of Xpert among PLWHA (70-100%) but the pooled
sensitivity of Xpert was generally lower among PLWHA (76%)
than HIV-uninfected subjects (89%) [23]. This heterogeneity
was partially explained by the high prevalence of smear
negativity among PLWHA.
Finally, intensified case finding (ICF) programs support
identification of earlier TB cases, especially with less advanced
TB disease and low bacterial burden, but potentially insufficient
to be detected using the Xpert assay. One third of culture-
confirmed active TB cases from an active pre-ART screening in
South Africa were false-negative using Xpert and this
phenomenon was associated with smear microscopy
negativity, prolonged duration to culture positivity, less likely to
have chronic cough and with less extensive radiological
abnormalities [46]. Moreover, Xpert-negative active TB cases
had less advanced HIV infection (higher CD4 count, lower
HIV-1 RNA levels and higher BMI). Similarly, Xpert-negative
cases in our report were more likely to have CD4 cell count
more than 100 cells/µL, but despite having longer median time
to culture positive (28 days compared to 21 days of Xpert-
positive cases), the difference was not statistically significant
(p=0.28). To examine this issue further, an analysis of the
impact and cost of alternative diagnostic algorithms in a high
TB/HIV co-infection setting projected that the addition of a
second Xpert test (Xpert/Xpert) performs similarly but less
expensively than the addition of culture (Xpert/culture) [47],
while chest radiography performed well as a ruling-out, rather
than rule-in, tool among Xpert-negative TB cases [48]. Empiric
data supporting these assertions, however, are lacking.
Moreover, the finding of the low reported NVP of Xpert in this
sample conforms the earlier studies of using Xpert as a rule-in
rather than rule-out tool in the diagnosis of active TB among
PLWHA [36]. On the other hand, Xpert was highly specific for
detecting M tuberculosis and rifampicin resistance in this
sample with no drug resistant case reported.
The deployment of Xpert in an intensified case finding
program may have an immediate and sustained impact on TB
epidemiology, but the finding that Xpert performed less than
ideal among HIV-infected inmates suggests the need to
explore combined diagnostic strategies [48–50]. In Brazil, a
similar socioeconomic country, symptom-based screening was
unreliable and regular mass radiographic screening was
concluded to have more pronounced impact on the prevalence
of active TB among prisoners [51,52]. There is a growing
Xpert in Intensified TB Case Finding in Prison
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evidence that, whenever resources allow, bacteriological
examination (smear microscopy and culture) should be
provided to all PLWHA, regardless of their symptom status
[53–57]. In high TB burden settings, culture yielded almost
double the number of TB cases detected by smear microscopy
and required fewer number needed to diagnose (NND)
compare to smear microscopy (8 compared to 19). This yield,
however, was more pronounced among HIV-infected compared
to HIV-uninfected individuals [58].
Our survey revealed a very high prevalence (12%) of
undiagnosed active TB in this prison’s HIV-infected population.
Negative consequences of missing active TB cases in
congregate settings are more pronounced compared to
community settings [59,60]. Reports from geographically-
distinct settings showed that several TB outbreaks, particularly
of MDR-TB in the community were linked to exposure in
prisons [61–63]. Additionally, missed infectious TB cases may
undermine TB control in such high-transmission closed
settings. Despite intensive TB control efforts, a single strain of
M tuberculosis persisted in a prison in the United States and
contributed to 50% of diagnosed TB cases over nine years.
This was attributed to infection/re-infection and reactivation of
latent TB infection (LTBI) among prisoners in contact with index
cases before being diagnosed [64]. Finding that more than one
third (38%) of pulmonary TB cases were missed in spite of a
regular screening program in a prison in the Cameroon,
Noeske et al questioned the possibility of ever achieving TB
control under any conditions of confinement [60]. Moreover,
missing pulmonary TB cases in prisons complicates the scaling
up of two major TB control interventions in high HIV prevalence
settings, namely isoniazid preventive therapy (IPT) and ART
[12,17,57,65–67]. An active case finding among ambulatory
PLWHA with good immunological status (CD4 count >200
cells/µL) showed that 8 of 10 PLWHA with no TB symptoms
were prescribed IPT for more than 4 weeks before the
bacteriological confirmation of their active TB status [10] and
may potentially contribute to isoniazid resistance since a single
drug was offered to active TB cases.
The overall TB prevalence (newly identified and previously
diagnosed TB cases) of 16.7% is one of the highest reported
prevalence of active TB from a prison setting worldwide and is
165 times higher than that in the Malaysian general population
[1,22]. It is well documented that prisoners come from
communities at elevated TB risk, and this may have contributed
to such high TB prevalence, among others. All, but one of the
study participants used illicit drugs before being incarcerated
and active TB disease was independently associated with
longer duration of drug use in this sample. Given this variable’s
co-linearity with age, it may be that longer duration of drug use
was associated with longer-standing HIV infection and
increased vulnerability to TB infection. Substance misuse,
particularly injection drug use, is a recognized independent risk
factor for LTBI and active TB disease [68]. The high prevalence
of tuberculin skin test positivity among PWID in a substance
abuse treatment center (86.7%) [69] and in another Malaysian
prison (87.6%) [70] confirmed the excess risk of LTBI among
this population in Malaysia. Moreover, TB remains a leading
cause of death among HIV infected PWID [71]. To better
control co-morbid illnesses among PWID, the WHO strongly
recommends the co-location of treatment for TB, HIV, and
opioid dependence using a “one-stop shopping” model of care,
but many countries facing the detrimental convergence of
these epidemics run these programs vertically [71–73]. The
availability and impact of utilizing new rapid diagnostic tools,
like the one used in this study, improve the likelihood of better
integration of services to treat multiple co-morbidities, yet
needs further empiric investigation.
Prisons have been identified as reservoirs for TB, ultimately
spreading the disease to the general population through prison
staff and released inmates. Increasing incarceration rates
alone was projected to increase TB and MDR-TB incidence in
civilian communities of the FSU [22,74]. Finding alternatives to
incarceration through penal reforms, particularly for PWID, in
an attempt to reduce overcrowding would likely reduce TB
burden in similar communities [74]. Proposed alternatives
include drug courts with alternatives to incarceration,
noncustodial measures, enhanced bail procedures and
adapted sentence policies [27]. In a similar setting, the
diversion of PWID from prisons into community-based
treatment facilities was a potential contributory factor leading to
the reported reduction in TB prevalence in 27 Thai prisons over
a six-year period [75].
Study limitations
Though the findings are compelling for the use of Xpert in TB
case finding among HIV-infected prisoners, this study is limited
by its small sample size. The cross-sectional survey is limited
in that it can only demonstrate associations and not causality,
but nonetheless, it was implemented, in a manner used by
prison-based screening efforts elsewhere to screen for active
TB. Moreover, the sample is entirely representative since all
HIV-infected prisoners in Malaysia’s largest prison were
sampled, including a high acceptance rate. Also, the lack of
available chest radiography limited our ability to use all TB
diagnostic modalities. Last, only a single Xpert assay was
deployed, perhaps reducing sensitivity, yet prisons experience
considerable budgetary constraints and this approach likely
represents real-world prison-based screening methods.
Conclusions
In this high HIV and TB prevalence setting, active case
finding using a single Xpert analysis has increased active
pulmonary TB case detection among HIV-infected Malaysian
prisoners. The new diagnostic tool is markedly superior to
sputum smear microscopy, however, missed almost half of
previously undiagnosed pulmonary TB cases (sensitivity of
53.3%) in the predominantly smear-negative sample. The
extraordinarily high TB prevalence reported here affirms the
importance of intensified TB case finding in congregate settings
and warrants further exploration of multiple diagnostic
approaches using the Xpert technology, potentially combined
with other diagnostic screening modalities in correctional
institutions with high HIV prevalence.
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